Veloxis Doses First Patient in Phase 2 Trial for OSE’s Kidney Transplant Drug
Event summary
- Veloxis dosed the first patient in the Phase 2 RENGEVITY-201 trial for pegrizeprument (VEL-101), a drug licensed from OSE Immunotherapeutics in 2021.
- Pegrizeprument targets CD28-mediated T cell activation to prevent organ rejection in kidney transplant recipients.
- The FDA granted Orphan Drug Designation to pegrizeprument for liver and heart transplant indications in 2025 and 2026, respectively.
The big picture
OSE Immunotherapeutics’ licensing deal with Veloxis in 2021 positioned the drug for global development, but success hinges on Veloxis’ execution in clinical trials and regulatory filings. The Phase 2 trial marks a critical step in validating pegrizeprument’s potential in kidney transplants, while prior FDA designations suggest strategic focus on high-need transplant indications.
What we're watching
- Clinical Progress
- The pace at which pegrizeprument advances through Phase 2 will determine its viability as a transplant rejection prevention therapy.
- Regulatory Strategy
- Whether Veloxis leverages the Orphan Drug Designations to accelerate approval timelines for liver and heart transplant indications.
- Commercial Potential
- How pegrizeprument’s dual mechanism of action differentiates it in the competitive landscape of transplant immunotherapies.
Related topics